After consultation with industry, the FDA published draft biosimilars guidelines in February 2012. Although details are lacking in a number of areas such as interchangeability, the guidance sets out the agency's broad views and gives developers greater certainty for the initiation of development programs.
The FDA published draft biosimilars guidelines in February 2012.
In the EU, the EMA has published guidance for the development of interferon beta biosimilars.
In order to meet physician and patient demands for more complex drugs and reduce the financial burden on payers, the Iranian government is keen to promote the Iranian biosimilars industry.
Browse more Biosimilar Market Research Reports